Related Experiment Video
Updated: Apr 21, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
New Horizons in Metabolic Health: Unveiling the Future of Drug Discovery and Development
Jinshan Zhao1,2, Quanyu Qiu1,2, Jidong Zhang3
1Department of Histology and Embryology, Zunyi Medical University, Zunyi 563000, China.
Introduction:
Metabolic diseases (diabetes, obesity, NAFLD) pose a severe threat to global health, demanding innovative drug solutions.
Methods:
This review systematically summarizes studies (2018-2025) on metabolic disease drug targets, innovative drug classes, and technological advancements, retrieved from PubMed, Embase, and Web of Science.
Results:
Key targets include PPARs (improving insulin resistance) AMPK (regulating energy metabolism) and gut microbiota-derived SCFAs; innovative drugs such as GLP-1 RAs (liraglutide) and SGLT2 inhibitors (dapagliflozin) show efficacy in glycemic control and liver protection; AI and CRISPR accelerate drug development.
Discussion:
Challenges include interindividual microbiota variability and long-term safety of new drugs.
Conclusion:
Target discovery, drug innovation, and technological progress offer new hope for metabolic disease treatment, with a future focus on multi-target therapy and precision medicine.
Related Concept Videos
Drug Discovery: Overview
Pharmacogenomics: Identification of New Drug Targets
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Pharmacogenetics of Drug Metabolism: Overview
Drug Biotransformation: Overview
Drug Biotransformation: Overview

